solbec option entitlement issue

The recently released letter to shareholders went someway to explaining where SBP is at and confirms the huge potential and exciting times that lie ahead for SBP.

SBP is trading at close to its yearly lows despite awaiting approval to commence it's Phase I trials.SBP is arguably about to enter is most advanced and exciting stage.

The value of the shares is enhanced even further with the entitlement to acquire a new 3 year Solbec option with an exercise price of only 12c, if exercised within the first 12 months.

With human trials expected to commence soon, these new options may prove to be very valuable.

Anyone with a view??